1. Home
  2. TGS vs TLX Comparison

TGS vs TLX Comparison

Compare TGS & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Transportadora de Gas del Sur SA TGS

TGS

Transportadora de Gas del Sur SA TGS

HOLD

Current Price

$31.40

Market Cap

3.4B

Sector

Utilities

ML Signal

HOLD

Logo Telix Pharmaceuticals Limited American Depositary Shares

TLX

Telix Pharmaceuticals Limited American Depositary Shares

HOLD

Current Price

$9.64

Market Cap

3.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TGS
TLX
Founded
1992
2015
Country
Argentina
Australia
Employees
N/A
N/A
Industry
Natural Gas Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
3.3B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TGS
TLX
Price
$31.40
$9.64
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$40.00
$21.00
AVG Volume (30 Days)
198.3K
95.0K
Earning Date
11-05-2025
01-01-0001
Dividend Yield
2.98%
N/A
EPS Growth
40.85
N/A
EPS
0.34
0.04
Revenue
$958,309,826.00
$664,225,558.00
Revenue This Year
$47.07
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$19.30
$225.26
Revenue Growth
N/A
55.35
52 Week Low
$19.74
$8.76
52 Week High
$34.37
$30.36

Technical Indicators

Market Signals
Indicator
TGS
TLX
Relative Strength Index (RSI) 58.47 46.99
Support Level $30.95 $9.37
Resistance Level $33.00 $9.93
Average True Range (ATR) 1.26 0.23
MACD -0.10 0.06
Stochastic Oscillator 64.29 69.14

Price Performance

Historical Comparison
TGS
TLX

About TGS Transportadora de Gas del Sur SA TGS

Transportadora de Gas del Sur SA is a transporters of natural gas in Latin America. The company's operating segments include Natural Gas Transportation, Midstream, Telecommunications, Production and Commercialization Liquids, Other Services, and Telecommunications. It generates maximum revenue from the Production and Commercialization of the Liquids segment. Geographically, it derives the majority of its revenue from Argentina.

About TLX Telix Pharmaceuticals Limited American Depositary Shares

Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.

Share on Social Networks: